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Methcathinone (ephedrone) is relatively easily accessible for abuse. Its users develop an
extrapyramidal syndrome and it is not known if this is caused by methcathinone itself, by
side-ingredients (manganese), or both. In the present study we aimed to clarify molecu-
lar mechanisms underlying this condition.We used microarrays to analyze whole-genome
gene expression patterns of peripheral blood from20methcathinone users and 20matched
controls. Gene expression proﬁle data were analyzed by Bayesian modeling and functional
annotation. Of 28,869 genes on the microarrays, 326 showed statistically signiﬁcant dif-
ferential expression with FDR adjusted p-values below 0.05. Quantitative real-time PCR
conﬁrmed differential expression for the most of the genes selected for validation. Func-
tional annotation and network analysis indicated activation of a gene network that included
immunological disease, cellular movement, and cardiovascular disease functions (enrich-
ment score 42). As HIV and HCV infections were confounding factors, we performed
additional stratiﬁcation of subjects. A similar functional activation of the “immunological
disease” category was evident when we compared subjects according to injection status
(past versus current users, balanced for HIV and HCV infection). However, this difference
was not large therefore the major effect was related to the HIV status of the subjects.
Mn–methcathinone abusers have blood RNA expression patterns that mostly reﬂect their
HIV and HCV infections.
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INTRODUCTION
Methcathinone (mcat) is an illicit stimulant drug synthesized by
oxidation of ephedrine or pseudoephedrine with potassium per-
manganate. Motor dysfunction, such as hypokinesia and impaired
balance, in methcathinone users has been reported in several
case series from different countries, and probably develops due
to chronic manganese intoxication (Sikk et al., 2007; Selikhova
et al., 2008; Stepens et al., 2008). As methcathinone is rela-
tively easy to manufacture using household materials, this poses
a signiﬁcant public health risk. Methcathinone abuse and its
preparation with potassium permanganate is quite common in
eastern European countries, but there are already signs that
the practice is spreading to western countries (De Bie et al.,
2007).
Molecular mechanisms underlying combined Mn and meth-
cathinone toxicity are poorly understood. Mn neurotoxicity is
well known and proposed mechanisms for neuronal death are
described in several review articles (Fitsanakis et al., 2006; Burton
and Guilarte, 2009; Curran et al., 2009). However, methcathinone
has a molecular structure similar to methamphetamine and its
pharmacodynamic properties suggest potential toxicity as well
(Glennon et al., 1995; Rockhold et al., 1997; McCann et al., 1998).
There are no molecular studies on the effect of these substances in
combination.
Gene expression proﬁling using whole-genome microarray
screening is a well-established technology to obtain a snapshot
of the complex response variables (transcriptome) in biological
systems. Expression proﬁling has great potential for examining
molecular pathogenesis and biomarkers of disease. It is a relatively
easy to use technology which gives a genome-wide overview of
the molecular changes during pathological conditions. Peripheral
blood gene expression has been used as a surrogate ﬁngerprint of
cerebral neurological diseases (Sharp et al., 2006; Sullivan et al.,
2006; Mohr and Liew, 2007; Davies et al., 2009). The resulting
proﬁle is a complex description of the molecular phenotype and
could be used to analyze different acute and chronic conditions.
The aim of this study was to analyze gene expression proﬁles
in chronic methcathinone abusers. In addition, we applied func-
tional genomic analysis to identify gene networks related to this
chronic condition.
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MATERIALS AND METHODS
STUDY PARTICIPANTS
Twenty illicit methcathinone users and 20 sex- and age-matched
controls reporting to be non-drug users andnot to be infectedwith
HIV and HCV were enrolled in the present study. Methcathinone
was themain drug of abuse. Subjects were divided according to self
reported drug abuse history into current or past users (reported
having discontinued at least 1 year previously). Main subject char-
acteristics including the results of motor and mental function and
quality of life assessment scales are summarized in Table 1 (Hoehn
and Yahr, 1967; Schwab and England, 1969; Folstein et al., 1975;
Fahn et al., 1987; Peto et al., 1995). All subjects were positive for
hepatitis C virus (HCV). Written informed consent was obtained
from all subjects. The study was approved by the ethics committee
on human research at Tartu University.
SAMPLE COLLECTION AND RNA PREPARATION
Blood samples from 20 subjects and 20 healthy controls were
collected into Tempus tubes (Applied Biosystems, Foster City,
USA). Blood was frozen and stored until further processing. RNA
extraction fromwhole bloodwas performed according to theman-
ufacturer’s protocol (PN 4379228C). After RNA extraction, alpha
and beta globin mRNA was depleted with GlobinClear Whole
Blood Globin Reduction kit (Ambion, Austin, USA). The quality
of RNAwas analyzedwith aBioanalyzer 2100 (Agilent,SantaClara,
USA) and gene expressionproﬁlingwas performedwithGeneChip
Human Gene 1.0 ST Arrays (Affymetrix, Santa Clara, USA) con-
taining probes for all exons of 28,869 genes. We analyzed all the
genes on the array without any ﬁltering for presence/absence cells.
MICROARRAY HYBRIDIZATION AND ANALYSIS
In order to label the RNA we used the Affymetrix GeneChip
Whole Transcript (WT) Sense Target Labeling Assay (Affymetrix,
Santa Clara, USA), which is designed to generate ampliﬁed and
biotinylated sense-strand targets from the entire expressed genome
without bias. Brieﬂy,double-stranded cDNAwas synthesized from
300 ng of total RNA by reverse transcription using random hexa-
mers tagged with a T7 promotor primer sequence. The double-
stranded cDNA was subsequently used as a template and ampli-
ﬁed by T7 RNA polymerase producing many copies of antisense
cRNA. In the second cycle of cDNA synthesis, random hexam-
ers were used to prime reverse transcription of the cRNA from
the ﬁrst cycle to produce single-stranded DNA in the sense ori-
entation. This DNA was fragmented with a combination of uracil
DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease
1 (APE 1). DNA was labeled by terminal deoxynucleotidyl trans-
ferase (TdT) and hybridization was performed according to the
manufacturer’s protocol. The arrays were subsequently washed,
stained with phycoerythrin streptavidin and scanned according
to standard Affymetrix protocol. Images were processed using the
Table 1 | Clinical and demographic characteristics.
Subject no. Sex Age
(years)
HIV History of
drug abuse
Duration of
use (years)
UPDRS Hoehn
andYahr
Schwab
and
England
PDQ-39 MMSE
1 M 47 pos Current 6 13 2,5 95 24 27
2 F 24 pos Past 1 27 2,5 80 23 30
3 M 44 pos Current 10 36 3 80 57 28
4 M 43 pos Current 4 17 2 90 9 25
5* M 42 pos Current 1 1 0 100 0 30
6 M 28 pos Current 2 19 2 95 53 29
7 M 37 pos Current 8 46 3 70 64 28
8 F 29 pos Current 11 12 2 90 46 29
9 M 35 neg Current 8 44 2 90 66 29
10 M 32 pos Past 2 73 4 55 61 30
11 M 33 neg Current 9 79 4 55 71 28
12 M 32 pos Current 13 50 3 70 55 28
13 M 36 neg Past 8 59 4 50 43 30
14 F 18 pos Past 2 22 3 75 44 30
15 M 28 pos Current 2 29 2,5 90 16 30
16 M 29 neg Current 2 42 3 80 39 30
17 M 44 neg Past 10 69 4 60 42 30
18 M 32 pos Past 1 26 3 85 60 30
19 M 28 pos Past 6 53 3 75 62 28
20 M 32 pos Current 9 61 2,5 85 51 30
UPDRS scores range from 0 to 176 (higher scores indicating more severe disability; Fahn et al., 1987). Hoehn and Yahr stages range from 1 to 5 (higher scores
indicating more severe disability; Hoehn andYahr, 1967). Schwab and England scores range from 0 to 100 (lower score indicating more severe disability; Schwab and
England, 1969). PDQ-39 scores from 0 to 100 (higher score indicating worse quality of life; Peto et al., 1995). MMSE scores range from 0 to 30 (scores under 23
indicating dementia; Folstein et al., 1975).
*Denotes the subject without clinically relevant extrapyramidal syndrome.
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Affymetrix Expression Console and the MAS 5.0 algorithm was
used to measure quality control parameters.
STATISTICAL ANALYSIS
The normalized, background subtracted, and modeled expression
(RobustMulti-arrayAnalysis, RMA) data (GEO accession number
GSE28686) were further analyzed using a linear model combined
with Bayesian moderation for standard errors implemented in
the Bioconductor limma package of the statistical software R1
(Ihaka and Gentleman, 1996; Smyth, 2004). False discovery rate
1http://www.r-project.org/
(FDR)was used to addressmultiple testing corrections (Benjamini
and Hochberg, 1995; Storey and Tibshirani, 2003). Moderated
model calculates B-value, which is the log-odd that the gene is
differentially expressed. B-statistics of zero corresponds to a 50-50
chance that the gene is differentially expressed and B-statistics is
automatically adjusted for multiple testing.
QUANTITATIVE REAL-TIME PCR ANALYSIS
Eight genes with signiﬁcant differences and with potentially inter-
esting functions from the gene expression proﬁling data were fur-
ther analyzed by means of real-time PCR (RT-PCR). These genes
were: C15orf26, GPR15, IGFR1, SNRPN, IFI44L, IFI44, IFI27, and
Table 2 | Differential expression analysis of the blood RNA suggests significant differences between study groups.
Probeset ID Gene symbol logFC AveExpr Adj. p-value B-value Gene title
8081214 GPR15 1.6 8.2 1.11E-04 10.199 G protein-coupled receptor 15
8046488 CDCA7 0.6 6.5 1.11E-04 9.901 Cell division cycle associated 7
7917283 MCOLN2 1.0 7.5 4.31E-04 8.329 Mucolipin 2
7964787 IFNG 1.1 7.1 0.001 7.697 Interferon, gamma
8081799 TIGIT 1.1 8.4 0.001 7.607 T cell immunoreceptor with Ig and ITIM domains
8038861 SIGLEC6 0.3 7.3 0.001 6.485 Sialic acid binding Ig-like lectin 6
8165653 ND1 0.4 13.2 0.001 6.463 NADH dehydrogenase, subunit 1 (complex I)
8175365 – 0.5 6.5 0.001 6.337 –
8165674 ND3 0.3 13.0 0.002 6.065 NADH dehydrogenase, subunit 3 (complex I)
8165648 C7orf11 0.5 12.5 0.002 6.027 Chromosome 7 open reading frame 11
7946563 – 0.6 11.3 0.002 5.917 –
7898793 C1QA 0.5 6.0 0.002 5.834 Complement component 1, q subcomponent, A chain
7903358 VCAM1 0.8 6.0 0.002 5.722 Vascular cell adhesion molecule 1
8149979 C8orf80 0.5 7.3 0.002 5.684 Chromosome 8 open reading frame 80
8169249 MID2 0.5 6.7 0.002 5.367 Midline 2
7983365 TRIM69 0.5 5.9 0.003 5.237 Tripartite motif-containing 69
8044154 CD8B 0.9 9.1 0.003 5.172 CD8b molecule
7944739 CRTAM 1.0 7.6 0.003 4.949 Cytotoxic and regulatory T cell molecule
8053584 CD8A 0.9 9.9 0.003 4.873 CD8a molecule
8109639 PTTG1 0.5 7.8 0.003 4.751 Pituitary tumor-transforming 1
7902660 WDR63 0.6 5.3 0.003 4.749 WD repeat domain 63
8019842 TYMS 0.8 6.7 0.003 4.682 Thymidylate synthetase
7948420 FABP5 1.0 6.5 0.003 4.662 Fatty acid binding protein 5 (psoriasis-associated)
8102643 CCNA2 0.6 6.8 0.003 4.653 Cyclin A2
7917576 GBP5 1.0 11.1 0.004 4.466 Guanylate binding protein 5
8002975 CDYL2 0.3 7.6 0.004 4.465 Chromodomain protein, Y-like 2
7930577 CASP7 0.5 8.1 0.004 4.455 Caspase 7, apoptosis-related cysteine peptidase
8151334 MSC 0.6 7.0 0.004 4.428 Musculin (activated B-cell factor-1)
7898535 – 0.3 3.9 0.004 4.367 –
8018352 SLC25A19 0.3 6.7 0.004 4.307 Solute carrier family 25 member 19
8053690 IGKC 1.0 9.4 0.004 4.291 Immunoglobulin kappa constant
7981962 SNRPN 0.6 7.1 0.004 4.159 Small nuclear ribonucleoprotein polypeptide N
7898805 C1QB 0.5 6.8 0.005 4.040 Complement component 1, q subcomponent, B chain
7940028 SERPING1 1.4 8.7 0.005 3.978 Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1
7986359 IGF1R 0.7 8.6 0.005 3.914 Insulin-like growth factor-1 receptor
8116130 FAM153B −0.6 6.9 0.005 3.898 Family with sequence similarity 153, member B
8043480 IGKV1OR15-118 0.9 10.9 0.005 3.863 Immunoglobulin kappa variable 1/OR15-118 pseudogene
Statistical analysis of Affymetrix GeneChip data was performed with the limma package for R (Smyth, 2004). For signiﬁcance analysis moderated t-statistics combined
with simple Bayesian model was used. “Probeset ID” is the Affymetrix ID for probes on the array, “Gene Symbol” is the ofﬁcial HUGO symbol for genes, “logFC” is
log2 fold change, “AveExpr” is average expression value (log2), “adj. p-value” is FDR adjusted p-value, “B-value” is log-odds that the gene is differentially expressed.
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IFNG. RNA was converted into cDNA using the High Capacity
cDNA Synthesis kit from Applied Biosystems. TaqMan assays and
Gene Expression Master mix was used for the RT-PCR reaction in
the SDS 7900 HT system (Applied Biosystems). Sample (20 con-
trols and 20 methcathinone users in four replicates) comparisons
were made using Welch’s t -test.
FUNCTIONAL ANNOTATION OF DIFFERENTIALLY EXPRESSED GENES
To deﬁne the functional networks of the differentially expressed
genes, data were analyzed by ingenuity pathway analysis (IPA,
Ingenuity Systems2). A data set containing Affymetrix probe-
set identiﬁers and corresponding fold change (log2) values was
uploaded. Each gene identiﬁer was mapped to its corresponding
gene object in the Ingenuity Pathways Knowledge Base to generate
2www.ingenuity.com
the list of focus genes. Networks of these focus genes were then
algorithmically generated based on inter-gene relationships man-
ually curated in the Ingenuity database from published studies.
Ingenuity pathway analysis calculates a signiﬁcance score for each
network. The score is generated using a p-value calculation, and
is displayed as the negative logarithm of that p-value. This score
indicates the likelihood that the assembly of a set of focus genes
into a network could be explained by chance alone (e.g. score of 2
indicates that there is a 1˚ in 100 chance that the focus genes are
together in a network by random chance).
RESULTS
GENE EXPRESSION PROFILING WITH MICROARRAYS
Comparison of the blood RNA samples isolated from meth-
cathinone users and healthy controls revealed distinct gene
expression proﬁles. Statistically signiﬁcant differential expres-
sion was observed for 326 genes with p-values less than 0.05
FIGURE 1 | Methcathinone users group distinctly on the
hierarchical clustering heatmap of blood gene expression levels.
The top 100 genes from the decreasing ordered list of moderated
t -values were clustered according to similarity in their gene
expression patterns. Signals are scaled to Z -scores of the rows. The
colored bar above the heatmap indicates the grouping variable – goldenrod
for methcathinone user, blue for controls. Column labels at the
bottom combine HIV status (positive or negative) with the drug user
status (current, past, never). Row labels are gene symbols and the
asterisk denotes the subject without clinically relevant extrapyramidal
syndrome. Note some overlap between the two groups at the middle of
the heatmap.
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(FDR adjusted for multiple testing, Table 2). The magnitudes
of expression signal differences (fold change or logFC) between
these two groups were generally low – 17 genes were upregu-
lated in the methcathinone user more than 1.1-fold and only
one gene was down-regulated more than 1.1-fold. However, the
B-statistics values for the list of genes were very high suggest-
ing real biological differences between these groups. A heatmap
(Figure 1) from unsupervised hierarchical clustering indicates
clear clustering of samples into drug users and non-users. How-
ever, in the middle of the heatmap, some overlap and mixture
between groups occurs. These mcat samples are persons with HIV
negative status. Therefore, HIV status has a signiﬁcant impact
on the gene expression proﬁle and is a strong confounding
factor.
A functional annotation analysis was performed to deﬁne
gene networks within the observed expression proﬁles. Rela-
tionships among the 326 genes signiﬁcantly different in meth-
cathinone users compared to control groups included two major
networks. The ﬁrst (with the highest score of 47; score indi-
cates the −log of enrichment p-value) contained genes anno-
tated with cell death, antigen presentation, or neurological dis-
ease functions (Table 3, Figure 2). A second network (score 42)
was related to immunological disease, cellular movement, or car-
diovascular disease. Enrichment or activation of these networks
suggests that methcathinone users have changes in the genetic
pathways related to the function of the nervous and immune
systems.
Table 2 includes many genes that are related to immune
response, andmay be differentially expressed compared to healthy
controls because most of drug users were HIV positive. We
therefore compared the subgroup of HIV negative drug users
to the healthy control group. In this comparison, no genes were
signiﬁcantly different at FDR less than 5%, but 93 genes were
different at or below a 30% FDR threshold (Table A1 in Appen-
dix). Annotation analysis for this dataset of HIV negative drug
users indicated up-regulation (23 genes, score 54) in a network
of genes with functions including hematological disease, cellu-
lar assembly, and organization or cell cycle (Table 3). In another
subgroup analysis we compared HIV positive subjects according
to their user status, current versus discontinued. This compari-
son should indicate the difference caused by active drug abuse
(Table 3). In this case both groups are HIV and HCV positive,
so infection status is balanced. The most signiﬁcantly enriched
network in this comparison included genes in the Genetic Dis-
order, Immunological Disease, or Cellular Movement categories
(25 genes, enrichment score 46). This network supports the
involvement of the immune system in the drug abuse induced
pathologies.
QUANTITATIVE REAL-TIME PCR
To further verify changes found with the GeneChip experi-
ment, we performed quantitative RT-PCR and analyzed gene
expression levels of eight selected genes. For seven genes, sta-
tistically signiﬁcant differential expression between 20 healthy
controls and 20 methcathinone users was seen in the expected
direction of change (C15orf26 p< 0.0001, GPR15 p< 0.0001,
IGFR1 p = 0.0002, SNRPN p = 0.038, IFI44L p = 0.0264, IFI27
Table 3 | Genetic networks significantly changed.
Molecules in network Score Focus
molecules
Top functions
IN METHCATHINONE USERS
BAK1,CD3,CHI3L2,ENG, EOMES, FBXO6, GBP5, GBP6, GBP7, GBP4 (includes
EG:115361), GCH1, growth hormone, HLA-DR, IFI27, IFI30, IFI44L, IFIT3, IFNG, KLF10,
MT1F
47 28 Cell death, antigen presentation,
neurological disease
AGER, C2, C1q, C1QA, C1QB, CCR5, CD80, CD81, CD40LG, complement component 1,
Creb, CXCR6 (includes EG:10663), ERK,IFI44, IFITM3, IFN&alpha;/&beta
42 24 Immunological disease, cellular
movement, cardiovascular disease
In HIV negative methcathinone users, compared to controls
Actin, adaptor protein 2, ANK1, Ap1, Ap2 alpha, AP2A1,calmodulin, caspase, CKS2,
clathrin, CLU, DAB2, EGF, EIF2AK1, EPB41, F actin, FKBP8, GNAS, GUK1, HDGF, HSPB1,
IgG, MPRIP, NFE2, NFkB (complex), NRGN
54 23 Hematological disease, cellular
assembly, and organization or cell
cycle
AGTR1B, ANKH, BAT3, betaestradiol, C14ORF45, CA2, CDKN1B, CKS2, CTSA, CUL2,
CUL4A, DGKD (includes EG:8527), GRINA, GYPA, HNF4A, MIR135A1, MIRLET7C, MMD,
NBL1, NEU1, PHOSPHO1, progesterone
31 15 Amino acid metabolism, cancer, cell
morphology
In HIV positive methcathinone users, compared by user status
AICDA, CARD8, CCNH, CD40, CD226, CXCL5, DDR1, EIF2AK1, EMP1, ERN1, GYPA,
IFIT1L, IFN beta, Iga, Ige, IgG, IGHA1, IGJ, IGLL1, Igm, IL1, IL12 (complex), IL1RAP,
interferon alpha, IRAK1BP1, KLF3, MAP4K5, NFkB (complex), NLRP1, RIOK3, Sapk,THBD,
TNFSF4, XCL1, ZNF675
46 25 Genetic disorder, immunological dis-
ease, cellular movement
14-3-3, adaptor protein 2, Ap1, ARHGEF12,CAMK2D, CCR3, CDC25A, CREG1, CSPG4,
DAB2, DENND4A, DLEU2, E2f, ERK, GAB1, hCG, HDLBP, histone h3, ITGB3, LDLRAP1,
LRRFIP1, Mapk, MAX, MYO10, ORC1L, PDGF BB, PGRMC1, Pkc(s), Ras, RGS13, RICS,
SKP1, STON2, TFDP2, YBX1
43 24 Cellular assembly and organization,
cancer, cell cycle
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FIGURE 2 | Annotation enrichment analysis indicated that a
network including “cell death, antigen presentation,
neurological disease” gene functions is significantly enriched
in the subjects with methcathinone abuse [score 47, score
is −log (p-value)]. Red nodes designate upregulated genes and the
number indicates log2 fold change (0 is for equal expression). Uncolored
nodes are genes in this network that were not in our list of differentially
expressed genes.
p = 0.0450, IFNG p< 0.0001). These results support the validity
of our microarray gene expression analysis.
DISCUSSION
In this study, we examined changes in gene expression proﬁles
in peripheral blood induced by methcathinone abuse. All but
one of the subjects had a clinically relevant extrapyramidal syn-
drome. RNA expression patterns of drug users clearly differed
from those of healthy controls. Also, RT-PCR results conﬁrmed
differences between these two groups. The overlap between con-
trols and HIV negative methcathinone users in the middle of the
heatmap (Figure 1) suggested thatmost of the hierarchical cluster-
ing was driven byHIV infection status. During recent years several
microarray studies of HIV induced alterations in host cell gene
expression have been performed using in vitro infected primary
cells, cell lines, or tissue samples (Giri et al., 2006). However, few
in vivo studies in HIV infected humans have evaluated expression
proﬁles of tissue samples (Masliah et al., 2004; Everall et al., 2005)
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or peripheral blood mononuclear cells (Motomura et al., 2004;
Kottilil et al., 2009;Monaco et al., 2009). Several of the same apop-
tosis, antigen presentation, and immune response genes (IFIT3,
IFI27, IFI44, IFNG, NFAT, STAT1, TCR, CCR5, ERK, IFITM3,
LY6E, IFNG, NFkB, OAS1, PLSCR1) described in previous HIV
microarray studies were upregulated in our analysis. Thus periph-
eral blood can be used for ﬁnding gene expression alterations in
HIV infected humans. Besides cell death and antigen presenta-
tion the genetic network with the highest score was also related to
neurological disease, consistent with known associations of HIV
infection and neurodegeneration (Clifford et al., 2005).
Further minor subgroup analysis of HIV negative users who
were all positive for HCV indicated that genes related to cell cycle,
cellular growth andproliferation, cancer, and cellular development
were upregulated compared to healthy controls. The same path-
ways have been shown to be involved in HCV induced hepatic
changes like cirrhosis, dysplasia, or hepatocellular carcinoma
(Wurmbach et al., 2007; De Giorgi et al., 2009).
As the aim of our study was to analyze the drug abuse effect,
we decided to stratify our group of subjects. We analyzed only
HIV and HCV positive subjects according to their injection sta-
tus (past versus current) and a clinical measure of the severity
of the neurological syndrome UPDRS. The most signiﬁcantly
enriched network after comparing HIV positive current and past
users included genes annotated with functions in Genetic Disor-
der, Immunological Disease, or Cellular Movement categories (25
genes, enrichment score 46). This network conﬁrms the involve-
ment of the immune system in drug abuse induced pathologies.
However, as both comparison groups had neurological symptoms
we can not draw any conclusions on the potential causes of the
extrapyramidal syndrome. On the other hand, injection status
seems to inﬂuence immune system and this is one factor involved
in the development of a neurodegenerative syndrome. Psychos-
timulant abuse has been shown to compromise immunological
status (Everall et al., 2005). Chronic Mn exposure has similar
effects on the immune system (Sengupta et al., 2007). Thus, both
of these factors have potential to induce neurodegeneration.
The UPDRS score reﬂects the clinical severity of the extrapyra-
midal syndrome. No signiﬁcant correlations were found between
the duration of Mn–methcathinone use and UPDRS or between
blood RNA proﬁles and UPDRS.
There are several limitations in our study. The main problem
is related to the sample organization. Our sample contains many
confounding factors – HIV and HCV infection, different duration
of methcathinone use, concomitant consumption of other drugs,
alcohol, and tobacco.Wehave not analyzed the clinical status of the
HIV and HCV infections. In addition, several drug abusers were
undernourished which makes identiﬁcation of a relevant control
group even more complicated. To overcome these limitations, we
have applied complex bioinformatics analytical tools in relatively
large samples (N = 20 in both groups) that allowed us to perform
some cohort stratiﬁcation. For further studies within methcathi-
none users more balanced control samples are needed. We have
tried to collect similar balanced sample as a control group, but due
to the speciﬁc and complex nature of our study group it is difﬁcult
and time consuming. Ideal controls would be either drug-freeHIV
andHCVpositive subjects or addicts abusing other drugs.We fully
understand the limitations caused by the complexity of the prob-
lemwe analyze.On the other hand, the situation of a non-balanced
control sample is quite common in clinical research.
ACKNOWLEDGMENTS
The ﬁnancial support by the Estonian Science Foundation (grant
7433) is acknowledged.
REFERENCES
Benjamini, Y., and Hochberg, Y. (1995).
Controlling the false discovery rate –
a practical and powerful approach to
multiple testing. J. R. Stat. Soc. Series
B Stat. Methodol. 57, 289–300.
Burton, N. C., and Guilarte, T. R.
(2009). Manganese neurotoxicity:
lessons learned from longitudinal
studies in nonhuman primates. Env-
iron. Health Perspect. 117, 325–332.
Clifford, D. B., Yang, Y., and Evans, S.
(2005). Neurologic consequences of
hepatitis C and human immunod-
eﬁciency virus coinfection. J. Neu-
rovirol. 11(Suppl. 3), 67–71.
Curran, C. P., Park, R. M., Ho, S. M.,
and Haynes, E. N. (2009). Incorpo-
rating genetics and genomics in risk
assessment for inhaled manganese:
from data to policy. Neurotoxicology
30, 754–760.
Davies, M. N., Lawn, S., Whatley,
S., Fernandes, C., Williams, R. W.,
and Schalkwyk, L. C. (2009). To
what extent is blood a reason-
able surrogate for brain in gene
expression studies: estimation from
mouse hippocampus and spleen.
Front. Neurogenomics 1:1–6. doi:
10.3389/fnins.2011.00161
De Bie, R. M., Gladstone, R. M.,
Strafella, A. P., Ko, J. H., and Lang,
A. E. (2007). Manganese-induced
Parkinsonism associated with meth-
cathinone (Ephedrone) abuse. Arch.
Neurol. 64, 886–889.
De Giorgi, V., Monaco, A., Worchech,
A., Tornesello, M., Izzo, F., Buon-
aguro, L.,Marincola, F. M.,Wang, E.,
and Buonaguro, F. M. (2009). Gene
proﬁling, biomarkers and pathways
characterizing HCV-related hepato-
cellular carcinoma. J. Transl. Med. 7,
85.
Everall, I., Salaria, S., Roberts, E.,
Corbeil, J., Sasik, R., Fox, H.,
Grant, I., and Masliah, E. (2005).
Methamphetamine stimulates inter-
feron inducible genes in HIV
infected brain. J. Neuroimmunol.
170, 158–171.
Fahn, S., Elton, R. L., and Commit-
tee, U. D. (1987). Uniﬁed Parkinson’s
Disease Rating Scale. Florham Park:
Macmillan.
Fitsanakis, V. A., Au, C., Erikson,
K. M., and Aschner, M. (2006).
The effects of manganese on glu-
tamate, dopamine and gamma-
aminobutyric acid regulation. Neu-
rochem. Int. 48, 426–433.
Folstein, M. F., Folstein, S. E., and
Mchugh, P. R. (1975). “Mini-mental
state”. A practical method for grad-
ing the cognitive state of patients
for the clinician. J. Psychiatr. Res. 12,
189–198.
Giri, M. S., Nebozhyn, M., Showe, L.,
andMontaner, L. J. (2006). Microar-
ray data on gene modulation by
HIV-1 in immune cells: 2000-2006.
J. Leukoc. Biol. 80, 1031–1043.
Glennon, R. A., Young, R., Martin, B.
R., and Dal Cason, T. A. (1995).
Methcathione (“cat”): an enan-
tiomeric potency comparison. Phar-
macol. Biochem. Behav. 50, 601–606.
Hoehn, M. M., and Yahr, M. D.
(1967). Parkinsonism: onset, pro-
gression and mortality. Neurology
17, 427–442.
Ihaka, R., and Gentleman, R. (1996).
R: a language for data analysis and
graphics. J. Comput. Graph. Stat. 5,
299–314.
Kottilil, S., Yan, M. Y., Reitano, K.
N., Zhang, X., Lempicki, R., Roby,
G., Daucher, M., Yang, J., Cortez,
K. J., Ghany, M., Polis, M. A.,
and Fauci, A. S. (2009). Human
immunodeﬁciency virus and hepati-
tis C infections induce distinct
immunologic imprints in peripheral
mononuclear cells. Hepatology 50,
34–45.
Masliah, E., Roberts, E. S., Langford,
D., Everall, I., Crews, L., Adame,
A., Rockenstein, E., and Fox, H. S.
(2004). Patterns of gene dysregula-
tion in the frontal cortex of patients
with HIV encephalitis. J. Neuroim-
munol. 157, 163–175.
McCann, U. D., Wong, D. F., Yokoi,
F., Villemagne, V., Dannals, R. F.,
and Ricaurte, G. A. (1998). Reduced
striatal dopamine transporter den-
sity in abstinent methamphetamine
and methcathinone users: evidence
from positron emission tomography
studies with [11C]WIN-35,428. J.
Neurosci. 18, 8417–8422.
www.frontiersin.org August 2011 | Volume 2 | Article 42 | 7
Sikk et al. Gene expression proﬁling in methcathinone abusers
Mohr, S., and Liew, C. C. (2007).
The peripheral-blood transcrip-
tome: new insights into disease and
risk assessment. Trends. Mol. Med.
13, 422–432.
Monaco, A., Marincola, F. M., Sabatino,
M., Pos, Z., Tornesello, M. L., Stron-
cek, D. F., Wang, E., Lewis, G.
K., Buonaguro, F. M., and Buon-
aguro, L. (2009). Molecular immune
signatures of HIV-1 vaccines in
human PBMCs. FEBS Lett. 583,
3004–3008.
Motomura, K., Toyoda, N., Oishi, K.,
Sato, H., Nagai, S., Hashimoto,
S., Tugume, S. B., Enzama, R.,
Mugewa, R., Mutuluuza, C. K.,
Mugyeyi, P., Nagatake, T., and Mat-
sushima, K. (2004). Identiﬁcation of
a host gene subset related to disease
prognosis of HIV-1 infected indi-
viduals. Int. Immunopharmacol. 4,
1829–1836.
Peto, V., Jenkinson, C., Fitzpatrick, R.,
and Greenhall, R. (1995). The devel-
opment and validation of a short
measure of functioning and well
being for individuals with Parkin-
son’s disease. Qual. Life Res. 4,
241–248.
Rockhold, R. W., Carlton, F. B. Jr.,
Corkern, R., Derouen, L., Bennett,
J. G., and Hume, A. S. (1997).
Methcathinone intoxication in the
rat: abrogation by dextrorphan.Ann.
Emerg. Med. 29, 383–391.
Schwab,R. S., andEngland,A.C. (1969).
Projection Technique for Evaluating
Surgery in Parkinson’s Disease. Edin-
burgh: EandS Livingstone.
Selikhova, M., Fedoryshyn, L.,
Matviyenko, Y., Komnatska, I.,
Kyrylchuk, M., Krolicki, L., Fried-
man, A., Taylor, A., Jager, H. R.,
Lees, A., and Sanotsky, Y. (2008).
Parkinsonism and dystonia caused
by the illicit use of ephedrone – a
longitudinal study. Mov. Disord. 23,
2224–2231.
Sengupta, A., Mense, S. M., Lan, C.,
Zhou, M., Mauro, R. E., Kellerman,
L., Bentsman, G.,Volsky, D. J., Louis,
E. D., Graziano, J. H., and Zhang,
L. (2007). Gene expression proﬁl-
ing of human primary astrocytes
exposed tomanganese chloride indi-
cates selective effects on several func-
tions of the cells.Neurotoxicology 28,
478–489.
Sharp, F. R., Xu, H., Lit, L., Walker, W.,
Apperson,M.,Gilbert,D. L.,Glauser,
T. A., Wong, B., Hershey, A., Liu, D.
Z.,Pinter, J.,Zhan,X., Liu,X.,Ran,R.
(2006). The future of genomic pro-
ﬁling of neurological diseases using
blood. Arch. Neurol. 63, 1529–1536.
Sikk, K., Taba, P., Haldre, S., Bergquist,
J., Nyholm, D., Zjablov, G., Asser,
T., and Aquilonius, S. M. (2007).
Irreversible motor impairment in
young addicts – ephedrone, man-
ganism or both? Acta. Neurol. Scand.
115, 385–389.
Smyth, G. K. (2004). Linear models
and empirical Bayes methods for
assessing differential expression in
microarray experiments. Stat. Appl.
Genet. Mol. Biol. 3, 1–26.
Stepens, A., Logina, I., Liguts,V., Aldins,
P., Eksteina, I., Platkajis, A., Martin-
sone, I., Terauds, E., Rozentale, B.,
and Donaghy, M. (2008). A Parkin-
sonian syndrome in methcathinone
users and the role of manganese. N.
Engl. J. Med. 358, 1009–1017.
Storey, J. D., and Tibshirani, R.
(2003). Statistical signiﬁcance for
genomewide studies. Proc. Natl.
Acad. Sci. U.S.A. 100, 9440–9445.
Sullivan, P. F., Fan, C., and Perou,
C. M. (2006). Evaluating the com-
parability of gene expression in
blood and brain. Am. J. Med. Genet.
B Neuropsychiatr. Genet. 141B,
261–268.
Wurmbach, E., Chen, Y. B., Khitrov,
G., Zhang,W., Roayaie, S., Schwartz,
M., Fiel, I., Thung, S., Mazzaferro,
V., Bruix, J., Bottinger, E., Fried-
man, S., Waxman, S., and Llovet,
J. M. (2007). Genome-wide mol-
ecular proﬁles of HCV-induced
dysplasia and hepatocellular carci-
noma. Hepatology 45, 938–947.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 14 March 2011; paper pend-
ing published: 27 April 2011; accepted: 22
June 2011; published online: 19 August
2011.
Citation: Sikk K, Kõks S, Soomets U,
Schalkwyk LC, Fernandes C, Haldre S,
Aquilonius S-M and Taba P (2011)
Peripheral blood RNA expression proﬁl-
ing in illicit methcathinone users reveals
effect on immune system. Front. Gene.
2:42. doi: 10.3389/fgene.2011.00042
This article was submitted to Frontiers in
Neurogenomics, a specialty of Frontiers in
Genetics.
Copyright © 2011 Sikk, Kõks, Soomets,
Schalkwyk, Fernandes, Haldre, Aquilo-
nius and Taba. This is an open-access
article subject to a non-exclusive license
between the authors and Frontiers Media
SA, which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and other Frontiers conditions are
complied with.
Frontiers in Genetics | Neurogenomics August 2011 | Volume 2 | Article 42 | 8
Sikk et al. Gene expression proﬁling in methcathinone abusers
APPENDIX
Table A1 | Expression analysis of the blood RNA between HIV negative drug users and the healthy control group.
Probeset ID Gene symbol logFC AveExpr adj. p-value B-value Gene title
7985352 C15orf26 −0.5 6.7 0.3736 −1.890 Chromosome 15 open reading frame 26
7982090 SNRPN 0.7 2.9 0.9245 −2.305 Small nucleolar RNA, C/D box 115-8
8018908 DNAH17 0.4 4.9 0.9245 −2.448 Dynein, axonemal, heavy chain 17
7942983 RNU6-2 0.3 4.0 0.9245 −2.574 RNA, U6 small nuclear 2
7893226 – −0.9 6.1 0.9245 −2.588
7982068 SNRPN 0.6 2.9 0.9245 −2.784 Small nucleolar RNA, C/D box 115-8
8059578 – 0.6 6.6 0.9245 −2.791 ENSG00000208057
7982056 SNRPN 0.7 3.5 0.9245 −2.821 Small nucleolar RNA, C/D box 115-8
8123336 SNORD45A 0.4 4.5 0.9245 −2.888 Small nucleolar RNA, C/D box 45A
8167947 – −1.3 4.4 0.9245 −2.894 ENSG00000211140
8081214 GPR15 1.1 7.6 0.9245 −2.922 G protein-coupled receptor 15
8146635 – 0.7 2.5 0.9245 −2.953 ENSG00000211143
7946054 HBG2 −1.9 11.1 0.9245 −2.963 Hemoglobin, gamma G
8165653 NDUFS1 −0.3 13.3 0.9245 −2.971 NADH-ubiquinone oxidoreductase chain 1
7922200 SELP −0.7 8.5 0.9245 −2.975 Selectin P (granule membrane protein 140 kDa, antigen CD62)
8051571 – 0.4 4.4 0.9245 −3.019 ENSG00000211163
7961102 CLEC1B −0.7 8.0 0.9245 −3.036 C-type lectin domain family 1, member B
7912582 LOC441873 0.6 5.1 0.9245 −3.048 PRAME family member 11
8015187 KRTAP1-4 0.4 8.8 0.9245 −3.052 Keratin associated protein 1-4
8172776 – −0.4 5.4 0.9245 −3.057 ENSG00000197185
7944876 NRGN −0.4 10.7 0.9245 −3.084 Neurogranin (protein kinase C substrate, RC3)
8112274 ELOVL7 −0.6 9.6 0.9245 −3.109 ELOVL family member 7, elongation of long chain fatty acids (yeast)
8041711 RNU6-2 0.4 4.2 0.9245 −3.117 RNA, U6 small nuclear 2
7961026 OVOS2 −1.0 6.5 0.9245 −3.143 Ovostatin 2
7905481 – 0.6 5.2 0.9245 −3.168 ENSG00000183586
8144719 LOC100271832 0.8 3.1 0.9245 −3.169 Hypothetical LOC100271832
8162529 – 0.4 6.3 0.9245 −3.178 ENSG00000209183
7982088 SNRPN 0.6 3.1 0.9245 −3.181 Small nucleolar RNA, C/D box 115-8
8130662 – 0.4 4.3 0.9245 −3.203 ENSG00000208409
7926889 LYZL1 0.5 4.0 0.9245 −3.205 Lysozyme-like 1
7913976 – 0.4 3.6 0.9245 −3.214 ENSG00000209703
7963208 – 0.4 3.5 0.9245 −3.222 ENSG00000210200
7915252 BMP8B 0.4 7.5 0.9245 −3.223 Bone morphogenetic protein 8b
8178205 HLA-DQA2 0.5 7.9 0.9245 −3.233 Major histocompatibility complex, class II, DQ alpha 1
8116313 LOC441120 0.4 6.1 0.9245 −3.249 Hypothetical protein LOC729569
7892934 – −0.6 7.1 0.9245 −3.275
8168687 RN5S9 0.5 4.7 0.9245 −3.280 RNA, 5S ribosomal 9
8063716 TUBB1 −0.5 11.6 0.9245 −3.293 Tubulin, beta 1
8111772 DAB2 −0.5 8.7 0.9245 −3.297 Disabled homolog 2
“Probeset ID” is the Affymetrix ID for probes on the array, “Gene Symbol” is the ofﬁcial HUGO symbol for genes, “logFC” is log2 fold change, “AveExpr” is average
expression value (log2), “adj. p-value” is FDR adjusted p-value, “B-value” is log-odds that the gene is differentially expressed.
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